Abstract: New technology may soon allow individuals to test themselves for chlamydia and gonorrhea. These new self-tests might help increase screening, but they will also bring new issues for treatment, prevention, and surveillance. Providers will need to decide how to respond to patients who present after a positive screening test and how to approach partner testing and treatment. Research will be needed to identify approaches to increase screening using these tests. Laboratory-based surveillance will not capture infections if testing does not involve a laboratory, so new surveillance techniques will be needed. Self-tests are new tools that will soon be available. We should be prepared to use them. N ew technology may soon allow individuals to test themselves for chlamydia (CT) and gonorrhea (GC), the 2 most commonly reported notifiable infections in the United States.
TESTS
Laboratory tests have evolved from culture-dependent to culture-independent platforms that use less-invasive specimen types. This has allowed for greater access to testing because of the ease of specimen collection and transport. However, the detection of sexually transmitted infections (STIs) has been largely limited to tests performed by skilled technicians in laboratories. 9 These tests are marketed in the United States following a rigorous review process prescribed by the Food and Drug Administration (FDA) to ensure accurate performance characteristics. Strict guidance for specimen collection, transport of specimens, test procedures, and reporting of results is detailed in the product insert of each test. There are no STI tests that have been cleared by the FDA for self-testing. There are Websites that allow persons to self-collect a specimen and mail it to a laboratory for testing. 10 The cost and validity of these tests are quite variable, and home collection of specimens has not been approved by the FDA.
Bridging gaps in STI testing through the development and deployment of self-tests has the potential to increase screening but must be carefully implemented. Potential problems include poor test accuracy and low predictive value. The performance of laboratory-based tests currently used to detect CT and GC is exceptionally high, with sensitivities of greater than 95% and specificities of greater than 99.5%. 9 The positive predictive value of a test is a function of test specificity and prevalence of infection within the test population and may be poor when the prevalence is low. The performance of future self-tests must be comparable with laboratory tests to minimize false positives and false negatives. Nevertheless, people will need to understand that tests are not perfect.
Laboratory-based nucleic acid amplification tests (NAATs) recommended by the Centers for Disease Control and Prevention identify CT and GC in clinical specimens by amplifying targetspecific nucleic acids for detection. 9 There are various methods used, but all rely on specific target amplification. Diagnostic test research has focused on microfluidic design of NAATs to maintain performance of laboratory tests yet allow for potential adaptation to self-tests. Targeting a specific gene sequence for amplification and detection requires a device that can perform these functions. Some approaches have used small stand-alone units to power amplification and detect the result, but these are likely impractical for self-tests. More promising are test cartridges that can be attached to smartphones for power and detection of amplified products. A smartphone application might also directly report a positive test result to the state or local health department and assist in linking patients to a provider for treatment, although such a link might discourage testing among persons who want to remain anonymous.
TREATMENT: WHO, WHEN, WHERE?
Laboratory-based NAATs are very sensitive and specific; however, it takes a few days to get results so presumptive treatment is recommended for persons with urethritis or cervicitis. Presumptive treatment is also recommended for all partners who have had sex with an infected person in the preceding 60 days because they may have incubating infections.
11 New self-tests are likely to have lower specificities than NAATs, but the likelihood of infection among persons with a positive self-test result would still be higher than that in some situations for which empiric treatment is recommended. Thus, treating patients who report that they have a positive self-test result, without doing confirmatory testing, seems reasonable.
Treating partners may be another challenge. Patients may want a higher level of certainty before notifying their partners than they require before treating themselves. Notifying a partner after a false-positive test result could unnecessarily strain a relationship [12] [13] [14] ; however, not notifying an infected partner may result in reexposure and reinfection of the index patient. 15, 16 Partner notification could be based on the index patient's history of a positive self-test result or a confirmatory rapid test of the patient at the clinician's office, or could await the result of a confirmatory NAAT (although this would require abstaining from sex with the partner in the interim). Confirmatory testing delays treatment and increases costs, and the increase in specificity brings a decrease in sensitivity. Approaches to treatment and partner treatment will require careful consideration.
Assuring the availability of low-cost and convenient treatment will be another issue, especially for persons who have asymptomatic infections that are easily ignored. Convenient walk-in clinics are increasingly used as a source of care for sexually transmitted disease. 17 Providers in these and other settings will need to develop protocols for managing patients who present to their clinics after a positive self-test result and consider a range of approaches from just treating the reported infection to offering a full sexual health evaluation.
PREVENTION
Screening young women for CT has been shown to prevent PID. 2 If screening and treatment reach high enough levels, it could also lower the prevalence of infection in the population. 18 Will self-tests lead to widespread testing? Some self-tests have been widely used, whereas others have not. Self-tests for pregnancy were introduced in the late 1970s, and now millions are sold every year. 19 Self-tests for HIV were approved by the FDA in 2012, but the current cost (approximately $40) exceeds what most individuals are willing to pay (approximately $17), especially when many clinics offer free or reduced price testing using a more accurate test. 20 Although self-tests are not yet available for other STIs, in some areas, persons can collect a specimen at home, mail it to a laboratory for testing, and receive their results within several days. A randomized controlled trial in Texas found that screening rates were higher for men who could mail in a urine specimen (72%) compared with men who had to visit a clinic for screening (48%). 21 A well-established program in Maryland and Washington, DC, that offers free mail-in testing for CT, GC, and trichomonas tested 858 specimens for 6 months in 2012. 22 A survey of young adults found that 93% thought self-tests were a "good idea," 73% thought people their age would use the tests, and they expected to pay an average of $23 per test. 23 How many will actually purchase and use a real self-test remains to be seen. Research will be needed to develop methods for promoting the use of self-tests.
SAVING SURVEILLANCE
Gonorrhea has been a reportable condition since 1941, and CT has been a reportable condition in all states since 2000. In 2015, GC (395,216) and CT (1,526,658) comprised 76% of all reported nationally notifiable infectious conditions. 1 Surveillance is based primarily on laboratories reporting all positive test results. Self-tests may complicate the ability to monitor trends in GC and CT because self-tests would bypass this established reporting system. If patients seek care after a positive self-test result and their provider sends another specimen to a laboratory for testing, those results would be captured. However, if self-test results are not confirmed by providers, or even if results are confirmed by other point-of-care tests performed in a clinician's office, they may not be captured. Providers could report all cases they treat, as is mandated in most jurisdictions; however, provider reporting is often incomplete. 24 Diagnoses might be inferred based on monitoring electronic records of medications prescribed, but the medications used to treat these infections are also used for many other infections. 25, 26 Perhaps electronic medical records could be used to directly identify diagnosed infections, but this technology is currently feasible in only a few areas. At this point, the way forward for surveillance is unclear. It would be advantageous to identify new approaches for surveillance now rather than wait until after the tests are widely used. This would allow comparison of reports from both before and after self-tests are introduced and help measure the impact on surveillance.
CONCLUSIONS
Self-tests for CT and GC have the potential to greatly expand testing. If self-tests lead to widespread screening and treatment, they could potentially decrease rates of PID and lower the prevalence of CTand GC. Although persons interested in a screening test may find that self-tests provide a major advantage by avoiding the need to visit a clinic, it is not so clear that young women are actively seeking a screening test. Currently, most screening is performed as recommended by clinicians in the context of a clinic visit for another reason. 27 Self-tests could be a major advance in the clinical setting because they will allow clinicians to diagnose and treat an infection at a single visit. Further research is needed to identify ways to increase demand for screening outside the clinical setting and to reduce the patient cost for an over-the-counter test. There are other barriers to overcome. Providers will need to establish protocols for treating patients and their partners. New surveillance techniques will be needed if treatment is based on testing done outside laboratories. Self-tests are new tools that will soon be available. We should be prepared to use them.
